Kolexia
Salles Gilles Médecine interne
Salles Gilles
Médecine interne
Hôpital Lyon Sud
Pierre-Bénite, France
1.1 K Activités
2 K Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Lymphomes Lymphome B Lymphome B diffus à grandes cellules Lymphome folliculaire Maladie de Hodgkin Lymphome malin non hodgkinien Leucémies Leucémie chronique lymphocytaire à cellules B Lymphome à cellules du manteau

Collaborateurs

Voir plus
Tilly Herve
Tilly Herve
Centre Henri-Becquerel, Rouen, France
Morschhauser Franck
Morschhauser Franck
Centre Hospitalier de Lille, Lille, France
Haioun Corinne
Haioun Corinne
Hôpital Henri Mondor, Créteil, France
Thieblemont Catherine
Thieblemont Catherine
Hôpital Saint-Louis, Paris, France

Industries

Voir plus
Novartis
10 collaboration(s)
Dernière en 2021
Celgene
7 collaboration(s)
Dernière en 2020
Abbvie
5 collaboration(s)
Dernière en 2021
Roche
3 collaboration(s)
Dernière en 2021

Dernières activités

Voir plus
A Dose Escalation Study of Glofitamab (RO7082859) as a Single Agent and in Combination With Obinutuzumab, Administered After a Fixed, Single Pre-Treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma: A Multicenter, Open-Label, Phase I/II Study to Evaluate the Safety, Efficacy, Tolerability and Pharmacokinetics of Escalating Doses of Glofitamab (RO7082859) as a Single Agent and in Combination With Obinutuzumab Administered After a Fixed, Single Dose Pre-Treatment of Obinutuzumab (Gazyva®/Gazyvaro™) in Patients With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma
Essai Clinique (Roche)   21 mars 2024
VaccHemInf: A Prospective Cohort Study of Efficacy, Safety and Characterization of Immune Response to Vaccinations in Hematopoietic Stem Cell Transplant Recipients
Essai Clinique (bioMérieux)   19 mars 2024
POLARIX: A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial Comparing the Efficacy and Safety of Polatuzumab Vedotin in Combination With Rituximab and CHP (R-CHP) Versus Rituximab and CHOP (R-CHOP) in Previously Untreated Patients With Diffuse Large B-Cell Lymphoma
Essai Clinique (Roche)   15 mars 2024
RELEVANCE: A PHASE 3 OPEN-LABEL RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF RITUXIMAB PLUS LENALIDOMIDE (CC-5013) VERSUS RITUXIMAB PLUS CHEMOTHERAPY FOLLOWED BY RITUXIMAB IN SUBJECTS WITH PREVIOUSLY UNTREATED FOLLICULAR LYMPHOMA The "RELEVANCE" Trial (Rituximab Lenalidomide Versus ANy ChEmotherapy)is Being Conducted as Two Companion Studies: RV-FOL-GELARC-0683 (N=750) and RV-FOL-GELARC-0683C (N=250); the Combined Total of 1000 Patients Enrolled in Both Studies Will be Analyzed.
Essai Clinique (Celgene)   13 mars 2024
Cell-free DNA from nail clippings as source of normal control for genomic studies in hematologic malignancies.
Haematologica   07 mars 2024
ElevateTN: A Randomized, Multicenter, Open-Label, 3 Arm Phase 3 Study of Obinutuzumab in Combination With Chlorambucil, Acalabrutinib (ACP-196) in Combination With Obinutuzumab, and Acalabrutinib Monotherapy in Subjects With Previously Untreated CLL
Essai Clinique (Acerta Pharma BV)   29 février 2024
ZUMA-5: A Phase 2 Multicenter Study of Axicabtagene Ciloleucel in Subjects With Relapsed/Refractory Indolent Non-Hodgkin Lymphoma (iNHL)
Essai Clinique (Gilead)   23 février 2024
Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With Hodgkin's Lymphoma: Prospective Controlled Trial in Clinical Stages I-II Supradiaphragmatic Hodgkin's Disease: Evaluation of Treatment Efficacy, (Long Term) Toxicity and Quality of Life in Two Different Prognostic Subgroups
Essai Clinique (Organisation européenne pour la recherche et le traitement du cancer)   21 février 2024
An Updated Comparison of Overall Survival with Brexucabtagene Autoleucel (Brexu-cel) CAR T-Cell Therapy (ZUMA-2) Versus Standard of Care (SCHOLAR-2) in Patients with Relapsed/Refractory Mantle Cell Lymphoma (R/R MCL) Previously Treated with a Covalent Bruton Tyrosine Kinase Inhibitor (BTKi)
Abstracts from the 2024 Tandem Meetings of ASTCT and CIBMTR, February 21-24, 2024, San Antonio, Texas, USA   01 février 2024
Functional precision oncology for follicular lymphoma with patient-derived xenograft in avian embryos.
Leukemia   15 janvier 2024